Loading data for ACXP — first visit, this takes a few seconds.

Alerta

Acurx Pharmaceuticals Inc... (ACXP)

NasdaqCM: ACXP · Precio en tiempo real · USD

1.44

+0.00 (0.00%)

Al cierre: Aug 19, 2026, 8:00 PM

1.44

+0.06%

Fuera de horario: 7:30 PM

0.00% (1D)

No hay datos disponibles

Precio de compra	1.06
Capitalización de mercado	6.19M
Ingresos (TTM)	n/a
Beneficio neto (TTM)	-7.51M
Beta	n/a
EPS (TTM)	-2.43
Ratio PER (TTM)	n/a
Adelante PE	-0.82
P/B (TTM)	0.83
P/S (TTM)	n/a
Earnings Date	Nov 11, 2026

Precio de venta	1.77
Volumen	268,814
Volumen medio (20D)	125,145
Abierto	1.45
Anterior Cerrar	1.44
Rango del día	1.37 - 1.49
Rango de 52 semanas	1.31 - 8.34
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de ACXP

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-pos...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Jun 25, 2021

Empleados 4

Bolsa de Valores NasdaqCM

Símbolo bursátil ACXP

Sitio web https://www.acurxpharma.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Acurx Pharmaceuticals fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -7.97M, una disminución de -43.51%.

Estados financieros

Sorpresa de resultados

Acurx Pharmaceuticals ha publicado sus resultados trimestrales en Aug 13, 2026:

Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.

EPS de -0.53 falla las estimaciones por -0.10, con 71.96% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Acurx Pharmaceuticals Inc. publique sus resultados el Nov 11, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

2 meses hace · Zacks

Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why

Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 meses hace · Moby

Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary

Moby summary of Acurx Pharmaceuticals, Inc.'s Q1 2026 earnings call

4 meses hace · Zacks

Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.

4 meses hace · GuruFocus.com

Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ...

Acurx Pharmaceuticals Inc (ACXP) reports improved financial stability and significant progress in clinical trials, despite ongoing challenges.

5 meses hace · Zacks

Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

Página 1 de 2

Acurx Pharmaceuticals Inc... (ACXP)